Elanco Animal Health Incorporated $ELAN Position Reduced by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. trimmed its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 80.2% in the third quarter, HoldingsChannel.com reports. The firm owned 153,063 shares of the company’s stock after selling 618,999 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Elanco Animal Health were worth $3,083,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Jennison Associates LLC raised its stake in shares of Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after buying an additional 2,468,122 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the period. Primecap Management Co. CA raised its position in Elanco Animal Health by 3.1% in the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after acquiring an additional 1,543,279 shares in the last quarter. Norges Bank acquired a new stake in Elanco Animal Health in the 2nd quarter valued at about $12,502,000. Finally, Brandes Investment Partners LP boosted its position in shares of Elanco Animal Health by 11.3% during the 2nd quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after purchasing an additional 820,901 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ELAN. Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $18.00 to $24.00 in a research report on Tuesday, October 7th. Stifel Nicolaus upped their price target on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, November 19th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.78.

Insiders Place Their Bets

In other Elanco Animal Health news, CFO Robert M. Vanhimbergen acquired 6,950 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average cost of $21.64 per share, for a total transaction of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares of the company’s stock, valued at $2,688,402.12. The trade was a 5.93% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey N. Simmons bought 22,000 shares of the stock in a transaction on Thursday, December 11th. The shares were acquired at an average cost of $21.75 per share, for a total transaction of $478,500.00. Following the purchase, the chief executive officer owned 167,000 shares in the company, valued at approximately $3,632,250. This represents a 15.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 43,450 shares of company stock valued at $937,883 in the last 90 days. Insiders own 0.89% of the company’s stock.

Elanco Animal Health Trading Up 0.7%

Elanco Animal Health stock opened at $22.38 on Thursday. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $23.70. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The firm has a market capitalization of $11.12 billion, a price-to-earnings ratio of 373.06, a P/E/G ratio of 3.40 and a beta of 1.86. The company has a 50 day moving average price of $22.04 and a 200 day moving average price of $18.55.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.